Investigational Drug Shows Potentialin Phase 3 Obesity Trial - Poll - MDSpire

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

  • By

  • Andrea Surnit

  • June 10, 2026

  • 4 min

Share

Original Source(s)

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

  • by Andrea Surnit

  • June 10, 2026

Related Content

Female Urology Clinicians Report More Harassment

Nearly half of female clinicians in urology reported experiencing patient-perpetrated sexual harassment or gender discrimination.

Study Reassures on Safety of Early NSAID Use

A large cohort found no adjusted link to major congenital malformations, but questions remain for miscarriage, later pregnancy, and other outcomes.

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.